RxDoctor Payments Data

Arvin Aranda, MD

Family Medicine · Owego, NYNPI 1609864792

Payments from drug & device makers

$4,204in general payments, 2019–2025

Across 201 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$908
  • Novo Nordisk$775
  • Pfizer$281
  • Boehringer Ingelheim$152
  • Lilly USA, LLC$144
  • plus $546 from 7 others

What the payments were for

  • Food & beverage$4,204100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,204 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$93,769
Medicare patients
453
Services billed
1,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$135,541
JanuviaSitagliptin Phosphate61$60,460
XareltoRivaroxaban61$58,220
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$44,297
JardianceEmpagliflozin34$38,828
OzempicSemaglutide17$19,855
FarxigaDapagliflozin Propanediol15$16,096
MounjaroTirzepatide12$13,016
MyrbetriqMirabegron14$12,471
Incruse ElliptaUmeclidinium Bromide21$11,062
ShingrixVaricella-Zoster Ge/As01b/Pf48$10,878
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$10,597
Breo ElliptaFluticasone/Vilanterol22$9,308
ArexvyRsvpref3 Antigen/As01e/Pf25$7,800
Atorvastatin Calcium631$7,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$281$135,541127 claims
GSKTrelegy Ellipta, Incruse Ellipta, Shingrix, Breo Ellipta, Arexvy$26$83,345172 claims
MerckJanuvia$39$60,46061 claims
Johnson & JohnsonXarelto$112$58,22061 claims
Boehringer IngelheimJardiance, Tradjenta$152$44,79346 claims
Novo NordiskOzempic$775$19,85517 claims
AstraZenecaFarxiga, Symbicort$1,398$19,19628 claims
Lilly USA, LLCMounjaro$144$13,01612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.

Other family medicine in Owego

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →